Skip to Main Content

Paper Details

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.
J Immunother Cancer
34
2016
BACKGROUND CAN, CONCLUSIONS, CR2, CR2 patients, CVac, DC, EOC, Patients, T cell, dendritic cell, epithelial ovarian cancer, mucin, mucin 1, ovarian cancer, patient, patients

Datasets

Release 1.2